Immune context governs stage-specific responses to depleting anti-PD-1 antibody in type 1 diabetes
Authors:
- Yujia ZhaiYZYujia Zhai
- Shuyun DongSDShuyun Dong
- Lauren C. NaatzLNLauren C. Naatz
- Tianxiao ZhangTZTianxiao Zhang
- Xiangyang YeXYXiangyang Ye
- Dean R. TantinDTDean R. Tantin
- Tallulah AndrewsTATallulah Andrews
- Mingnan ChenMCMingnan Chen
Open Access
- 22 May 2026
- journal article
- Published by Elsevier in Cell Biomaterials
Abstract
No abstract availableFunding Information
- University of Utah
- National Multiple Sclerosis Society
- National Institutes of Health (AI139535)
This publication has 87 references indexed in Scilit:
- Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin deliveryActa Biomaterialia, 2025
- Biomaterial-driven 3D scaffolds for immune cell expansion toward personalized immunotherapyActa Biomaterialia, 2025
- Interferons are key cytokines acting on pancreatic islets in type 1 diabetesDiabetologia, 2024
- Use of teplizumab in children and adolescents at risk of type 1 diabetes: perspectives of parents and caregivers from an Italian Pediatric Diabetes CenterActa Diabetologica, 2024
- Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cellsProtein Science, 2023
- Nanotargeted Delivery of Immune Therapeutics in Type 1 DiabetesAdvanced Materials, 2023
- Circulating CXCR5−PD-1hi peripheral T helper cells are associated with progression to type 1 diabetesDiabetologia, 2019
- B cell depletion reduces T cell activation in pancreatic islets in a murine autoimmune diabetes modelDiabetologia, 2018
- The resident macrophages in murine pancreatic islets are constantly probing their local environment, capturing beta cell granules and blood particlesDiabetologia, 2018
- Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responsesEuropean Journal of Immunology, 2003